Oncotelic Therapeutics, Inc. (OTLC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 600K 1.2M 1.8M Q4 '12: 156K Q4 '20: 1.7M Q4 '12 Q4 '20

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-18M -12M -6M 0 6M 12M 18M Q3 '16: -14.3M Q4 '16: -13.8M Q1 '17: -14.4M Q2 '17: -14.6M Q3 '17: -14.9M Q4 '17: -13.8M Q1 '18: -10.7M Q2 '18: -6.9M Q3 '18: -3.6M Q4 '18: -712.7K Q1 '19: -893.8K Q2 '19: -1.9M Q3 '19: -2.6M Q4 '19: -4.3M Q1 '20: -6M Q2 '20: -4.8M Q3 '20: -5.5M Q4 '20: -7.6M Q1 '21: -7M Q2 '21: -10.8M Q3 '21: -10.9M Q4 '21: -9.1M Q1 '22: -11.4M Q2 '22: -7.9M Q3 '22: -6.7M Q4 '22: -9.7M Q1 '23: -5.6M Q2 '23: -11.7M Q3 '23: -11.1M Q4 '23: -6.7M Q1 '24: -6.6M Q2 '24: -362.8K Q3 '24: -3.7M Q4 '24: -3.6M Q1 '25: -3.5M Q2 '25: -3.5M Q3 '25: -689.5K Q4 '25: -3.2M Q1 '26: -4.9M Q2 '26: -5.7M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-90M 0 90M 180M 270M Q3 '16: -14.2M Q4 '16: -13.7M Q1 '17: -14.3M Q2 '17: -14.5M Q3 '17: -14.8M Q4 '17: -13.8M Q1 '18: -10M Q2 '18: -6.3M Q3 '18: -3M Q4 '18: -712.7K Q1 '19: -1.5M Q2 '19: -2.5M Q3 '19: -3.3M Q4 '19: -6.6M Q1 '20: -10.3M Q2 '20: -8.5M Q3 '20: -9.5M Q4 '20: -9.5M Q1 '21: -7.6M Q2 '21: -11.5M Q3 '21: -11M Q4 '21: -9.4M Q1 '22: -11.4M Q2 '22: 7.8M Q3 '22: 8.6M Q4 '22: 5.1M Q1 '23: 9.4M Q2 '23: -13.3M Q3 '23: -12.5M Q4 '23: -7.9M Q1 '24: -7.8M Q2 '24: -1.2M Q3 '24: -4.7M Q4 '24: -4.5M Q1 '25: -4.4M Q2 '25: -3.9M Q3 '25: -1.7M Q4 '25: 249.3M Q1 '26: 247.4M Q2 '26: 247.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-18M -12M -6M 0 6M 12M 18M Q3 '16: -14M Q4 '16: -15.2M Q1 '17: -14.5M Q2 '17: -14.3M Q3 '17: -14.4M Q4 '17: -10.9M Q1 '18: -8.1M Q2 '18: -3.9M Q3 '18: -993.9K Q4 '18: -241K Q1 '19: 523K Q2 '19: -1.1M Q3 '19: -1.4M Q4 '19: -2.3M Q1 '20: -2.1M Q2 '20: -1.1M Q3 '20: -2.3M Q4 '20: -2.8M Q1 '21: -4.1M Q2 '21: -5.5M Q3 '21: -4.9M Q4 '21: -4.4M Q1 '22: -4.1M Q2 '22: -3.1M Q3 '22: -2.4M Q4 '22: -1.5M Q1 '23: -740.9K Q2 '23: -986.3K Q3 '23: -1M Q4 '23: -1.3M Q1 '24: -1.3M Q2 '24: -1.1M Q3 '24: -1M Q4 '24: -740.3K Q1 '25: -675.8K Q2 '25: -540.2K Q3 '25: -704K Q4 '25: -1.4M Q1 '26: -1.6M Q2 '26: -1.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 200M 400M 600M Q2 '19: 65.4M Q2 '20: 94.7M Q3 '20: 89M Q1 '21: 94.2M Q2 '21: 369.5M Q3 '21: 370.4M Q1 '22: 377.4M Q2 '22: 418.8M Q3 '22: 386.8M Q1 '23: 392.4M Q2 '23: 394.4M Q3 '23: 397.8M Q1 '24: 399.4M Q2 '24: 401.6M Q3 '24: 407.3M Q1 '25: 407.4M Q2 '25: 452.8M Q3 '25: 426.4M Q1 '26: 443.8M Q2 '26: 467.9M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.75 -0.50 -0.25 0.00 0.25 0.50 0.75 Q3 '16: -0.54 Q4 '16: -0.52 Q1 '17: -0.54 Q2 '17: -0.55 Q3 '17: -0.56 Q4 '17: -0.52 Q1 '18: -0.40 Q2 '18: -0.28 Q3 '18: -0.19 Q4 '18: -0.13 Q1 '19: -0.24 Q2 '19: -0.23 Q3 '19: -0.20 Q4 '19: -0.11 Q1 '20: -0.02 Q2 '20: 0.01 Q3 '20: 0.00 Q4 '20: -0.10 Q1 '21: -0.08 Q2 '21: -0.10 Q3 '21: -0.08 Q4 '21: -0.04 Q1 '22: -0.02 Q2 '22: 0.03 Q3 '22: 0.03 Q4 '22: 0.01 Q1 '23: 0.02 Q2 '23: -0.04 Q3 '23: -0.04 Q4 '23: -0.02 Q1 '24: -0.02 Q2 '24: 0.00 Q3 '24: -0.01 Q4 '24: -0.01 Q1 '25: -0.01 Q2 '25: -0.01 Q3 '25: 0.00 Q4 '25: 0.59 Q1 '26: 0.59 Q2 '26: 0.59 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.